medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 6

<< Back Next >>

Ann Hepatol 2018; 17 (6)

Gene Therapy for Treatment of Chronic Hyperammonemia in a Rat Model of Hepatic Encephalopathy

Espíritu-Ramírez P, Ortega-Balderas NY, Sevilla-Tapia L, Montiel-Martínez AG, Pastor-Flores AR, Palomares LA, Torres-Vega MA

Language: English
References: 37
Page: 1026-1034
PDF size: 290.72 Kb.


ABSTRACT

Introduction and aim. Hepatic encephalopathy (HE), caused by hyperammonemia resulting from liver disease, is a spectrum of neuropsychiatric and motor disorders that can lead to death. Existing therapies are deficient and alternative treatments are needed. We have shown that gene therapy with a baculovirus vector containing the glutamine synthetase (Bac-GS) gene is efficient for reducing ammonia levels in an acute hyperammonemia rat model. However, the most common condition resulting from liver disease is chronic hyperammonemia. In this work, Bac-GS was evaluated in bile-duct ligated rats, a chronic liver disease model with hyperammonemia and some characteristics of Type C HE. Material and methods. Bac-GS was tested for mediating GS overexpression in HeLa cells and H9C2 myotubes. For determining the utility of Bac-GS for the reduction of ammonia levels in a chronic hyperammonemia animal model, four groups of rats were treated: control, sham, ligated with Bac-GS and ligated with Bac-GFP. Baculoviruses were injected i.m. 18 days post-surgery. Blood was drawn 2, 3 and 4 weeks post-surgery and plasma ammonia concentrations were quantified. Results. In protein lysates of cells and myotubes transduced with Bac-GS, a 44 kDa band corresponding to GS was detected. Significant results were obtained in the hyperammonemic bile-duct ligated rat model, as plasma ammonia was reduced to normal levels 3 days after treatment with Bac-GS. Furthermore, a transitory effect of Bac-GS was observed. Conclusion. Our results show that gene therapy by delivering GS is a promising alternative for treatment of hyperammonemia in acute-on-chronic liver failure patients with HE.


REFERENCES

  1. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.

  2. Suraweera D, Sundaram V, Saab S. Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions. Gut Liver 2016; 10: 509-19.

  3. Citro V, Milan G, Tripodi FS, Gennari A, Sorrentino P, Gallotta G, Postiglione A, et al. Mental status impairment in patients with West Haven grade zero hepatic encephalopathy: the role of HCV infection. J Gastroenterol 2007; 42: 79-82.

  4. Felipo V. Hepatic encephalopathy: effects of liver failure on brain function. Nat Rev Neurosci 2013; 14: 851-8.

  5. Sawhney R, Holland-Fischer P, Rosselli M, Mookerjee R, Agarwal B, Jalan R. Role of ammonia, inflammation and cerebral oxygenation in brain dysfunction of acute on chronic liver failure patients. Liver Transpl 2016; 22: 732-42.

  6. Vierling JM, Mokhtarani M, Brown RS Jr, Mantry P, Rockey DC, Ghabril M, Rowell R, et al. Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2016; 14: 903-6.

  7. Iwasa M, Sugimoto R, Mifuji-Moroka R, Hara N, Yoshikawa K, Tanaka H, Eguchi A, et al. Factors contributing to the development of overt encephalopathy in liver cirrhosis patients. Metab Brain Dis 2016; 31: 1151-6.

  8. Oja SS, Saransaari P, Korpi ER. Neurotoxicity of Ammonia. Neurochem Res 2017; 42: 713-20.

  9. Aghaei I, Hajali V, Dehpour A, Haghani M, Sheibani V, Shabani M. Alterations in the intrinsic electrophysiological properties of Purkinje neurons in a rat model of hepatic encephalopathy: Relative preventing effect of PPARγ agonist. Brain Res Bull 2016; 121: 16-25.

  10. Davuluri G, Krokowski D, Guan BJ, Kumar A, Thapaliya S, Singh D, Hatzoglou M, et al. Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of lleucine in cirrhosis. J Hepatol 2016; 65: 929-37.

  11. Jalan R, De Chiara F, Balasubramaniyan V, Andreola F, Khetan V, Malago M, Pinzani M, et al. Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension. J Hepatol 2016; 64: 823-33.

  12. Butterworth RF. Pathogenesis of hepatic encephalopathy in cirrhosis: the concept of synergism revisited. Metab Brain Dis 2016; 31: 1211-15.

  13. Rahimi RS, Rockey DC. Hepatic Encephalopathy: Pharmacological Therapies Targeting Ammonia. Semin Liver Dis 2016; 36: 48-55.

  14. Torres-Vega MA, Vargas-Jerónimo RY, Montiel-Martínez AG, Muñoz-Fuentes RM, Zamora-Carrillo A, Pastor AR, Palomares LA. Delivery of glutamine synthetase gene by baculovirus vectors: a proof of concept for the treatment of acute hyperammonemia. Gene Ther 2015; 22: 58-64.

  15. Makkonen KE, Airenne K, Ylä-Herttulala S. Baculovirus-mediated gene delivery and RNAi applications. Viruses 2015; 7: 2099-125.

  16. Mansouri M, Bellon-Echeverria I, Rizk A, Ehsaei Z, Cianciolo Cosentino C, Silva CS, Xie Y, et al. Highly efficient baculovirus- mediated multigene delivery in primary cells. Nat Commun 2016; 7: 11529. doi: 10.1038/ncomms11529.

  17. Palomares LA, Realpe M, Ramírez OT. An Overview of Cell Culture Engineering for the Insect Cell-Baculovirus Expression Vector System (BEVS). In: Al-Rubeai M (ed.). Animal Cell Culture, Cell Engineering 9. Chapter 15. Switzerland: Springer International Publishing; 2015, p. 501-19.

  18. Kwang TW, Zeng X, Wang S. Manufacturing of AcMNPV baculovirus vectors to enable gene therapy trials. Mol Ther Methods Clin Dev 2016; 3: 15050. doi:10.1038/mtm.2015.50. eCollection 2016.

  19. Butterworth RF, Norenberg MD, Felipo V, Ferenci P, Albrecht J, Blei AT. Experimental models of hepatic encephalopathy: ISHEN guidelines. Liver Int 2009; 29: 783-8.

  20. Mena JA, Ramírez OT, Palomares LA. Titration of non-occluded baculovirus using a cell viability assay. Biotechniques 2003; 34: 260-4.

  21. Kimes BW, Brandt BL. Properties of a clonal muscle cell line from rat heart. Exp Cell Res 1976; 98: 367-81.

  22. Giménez-Garzó C, Salhi D, Urios A, Ruíz-Sauri A, Carda C, Montoliu C, Felipo V. Rats with Mild Bile Duct Ligation Show Hepatic Encephalopathy with Cognitive and Motor Impairment in the Absence of Cirrhosis: Effects of Alcohol Ingestion. Neurochem Res 2015; 40: 230-40.

  23. Jover R, Rodrigo R, Felipo V, Insausti R, Sáez-Valero J, García-Ayllón MS, Suárez I, et al. Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: a model of hepatic encephalopathy in cirrhosis. Hepatology 2006; 43: 1257-66.

  24. Kaplan A. Urea, nitrógeno and urinary ammonia. In: Meites S (ed.). Standard Methods of Clinical Chemistry. New York: Academic Press Inc; 1965, p. 245-56.

  25. Condreay JP, Witherspoon SM, Clay WC, Kost TA. Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector. Proc Natl Acad Sci USA 1999; 96: 127-32.

  26. Tag CG, Weiskirchen S, Hittatiya K, Tacke F, Tolba RH, Weiskirchen R. Induction of experimental obstructive cholestasis in mice. Lab Anim 2015; 49: 70-80.

  27. Pieroni L, Maione D, La Monica N. In vivo gene transfer in mouse skeletal muscle mediated by baculovirus vectors. Hum Gene Ther 2001; 12: 871-81.

  28. Luo WY, Lin SY, Lo KW, Lu CH, Hung CL, Chen CY, Chang CC, et al. Adaptive immune responses elicited by baculovirus and impacts on subsequent transgene expression in vivo. J Virol 2013; 87: 4965-73.

  29. Miyashita T, Enosawa S, Suzuki S, Tamura A, Tanaka H, Amemiya H, Matsumura T, et al. Development of a bioartificial liver with glutamine synthetase-transduced recombinant human hepatoblastoma cell line, HepG2. Transplant Proc 2000; 32: 2355-58.

  30. Tang NH, Wang XQ, Li XJ, Chen YL. Ammonia metabolism capacity of HepG2 cells with high expression of human glutamine synthetase. Hepatobiliary Pancreat Dis Int 2008; 7: 621-7.

  31. van Wenum M, Adam AA, Hakvoort TB, Hendriks EJ, Schevchenko V, van Gulik TM, Chamuleau RA, et al. Selecting Cells for Bioartificial Liver Devices and the Importance of a 3D Culture Environment: A Functional Comparison between the HepaRG and C3A Cell Lines. Int J Biol Sci 2016; 12: 964-78.

  32. Díaz-Gómez D, Jover M, del-Campo JA, Galindo A, Romero- Gómez M. Experimental models for hepatic encephalopathy. Rev Esp Enferm Dig 2011; 103: 536-41.

  33. Hakvoort TB, He Y, Kulik W, Vermeulen JL, Duijst S, Ruijter JM, Runge JH, et al. Pivotal role of glutamine synthetase in ammonia detoxification. Hepatology 2017; 65: 281-93.

  34. Rivera VM, Gao GP, Grant RL, Schnell MA, Zoltick PW, Rozamus LW, Clackson T, et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 2005; 105: 1424-30.

  35. Moreira C, Ramos MJ, Fernandes PA. Glutamine Synthetase Drugability beyond Its Active Site: Exploring Oligomerization Interfaces and Pockets. Molecules 2016; 21: pii: E1028. doi: 10.3390/molecules21081028.

  36. Spodenkiewicz M, Diez-Fernandez C, Rüfenacht V, Gemperle- Britschgi C, Häberle J. Minireview on Glutamine Synthetase Deficiency, an Ultra-Rare Inborn Error of Amino Acid Biosynthesis. Biology (Basel) 2016; 5: pii: E40. doi:10.3390/ biology5040040.

  37. Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol 2016; 65: 1232-44.




2020     |     www.medigraphic.com